Viral Vaccine Trends and Forecast
The future of the global viral vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier markets. The global viral vaccine market is expected to reach an estimated $76.3 billion by 2030 with a CAGR of 8.1% from 2024 to 2030. The major drivers for this market are increasing prevalence of infectious diseases, increase in funding for the development of new vaccines, and rise in chronic infections among population.
• Lucintel forecasts that, within the type category, preventive will remain the larger segment over the forecast period.
• Within the distribution channel category, hospital & retail pharmacies will remain the largest segment.
• In terms of region, North America will remain the largest region over the forecast period.
A more than 150-page report is developed to help in your business decisions.
Emerging Trends in the Viral Vaccine Market
A few changes include technological improvements, changes in public health factors, and how people perceive the market for vaccines and viral vaccines. Further, barriers to change are eroding, and changes are increasingly facilitated in the foreseeable future. Some of these changes include technological updates, changes in public health factors, and a shift in how the market for vaccines and viral vaccines is perceived. Barriers to change are being lifted, and change is becoming more possible in the near term. Several changes include technological enhancements, changes in public health factors, and how people see the market for vaccines and viral vaccines.
• mRNA Vaccine Technology: The successful deployment of mRNA vaccines during the COVID-19 pandemic has revived a desire for the use of this technology in the development of vaccines against other viral diseases. Other companies are studying mRNA vaccines targeting influenza, RSV, and other viral diseases. This phenomenon involves more than an appreciation for the need for vaccines; it also brings more urgency and nimbleness in the capacity to respond to potential future viral threats. This means that mRNA technology will form an important part of the future of vaccine development.
• Multivalent Vaccines: Increasing attention is being paid to multivalent vaccines, which are designed to contain more than one kind of viral antigen and will therefore elicit an immune response against more than one kind of virus. It must be emphasized that this trend is most pertinent for influenza and COVID-19 viruses, as these may have many circulating variants at any one time. Patient satisfaction and inclination to take vaccines would also improve through the use of multivalent vaccines, which increase efficacy and decrease the number of doses required. Being able to create these vaccines would significantly improve the global approach to preventing viral pandemics.
• Global Vaccine Access Programs: The COVID-19 pandemic revealed access inequities in vaccines across the globe and created a greater emphasis on global vaccine equity. There are a growing number of initiatives ensuring that low- and middle-income nations have enough vaccines. Various entities and populations are working together to increase the capacity for mass production and effective distribution of services in areas of great need. This trend is important in enhancing health systems globally and preventing future outbreaks.
• New Ways of Vaccination: New technology and improvements in understanding genomics and immunology are changing the way vaccines are developed and administered to fit an individual’s genetic composition. This aims to improve the effectiveness of vaccines by considering age, health, and genetic factors. Such vaccines could be more effective than standard ones. These vaccines are designed to produce stronger immune responses while reducing side effects, thus improving efficacy and safety among different population groups.
• Funding Intensifies for Vaccine Research: Governments and private agencies are increasing the amount of funds they spend on vaccine research and viral vaccination development. This trend is driven by the ability to respond to viral threats and the experience gained from COVID-19. Increased financial support promotes the development of new solutions for vaccine technologies, production, and storage and delivery. This influx of investment is expected to accelerate innovation and the range of viruses that vaccines can potentially cover.
The current trends in the domestic market attest to the volatility of the viral vaccine market. As technologies are being incorporated, there is a drive toward global justice, and proper virus containment is being customized in a more satisfying manner.
Recent Developments in the Viral Vaccine Market
Several recent developments in the viral vaccine market reflect technological improvements, cooperative relationships, and regulatory changes. This approach focuses on the newest drivers of the market, considering five noteworthy changes in viruses and cancer.
• Fast-Tracked Creation of Vaccines for New Viruses: The recent COVID-19 pandemic saw the most rapid development of vaccine pools, as regulatory bodies were forced to make certain modifications in approval processes. Clinical trials that take less time and emergency use permissions have now become the order of the day to ensure effective and fast responses to viral infections. This development sets a fresh benchmark for how fast vaccines can be developed for new viral outbreaks, such as in public health emergencies.
• Emphasis on Combination Vaccines: There is an increasing trend in research focusing on administering combination vaccines to protect against several viruses with a single-shot administration. The strategic plan to incorporate vaccines for both COVID-19 and the flu into a single administration system is expected to improve health outcomes. Although this technique is beneficial to public health because it reduces the number of visits per patient, it is also more effective, as it provides a wider scope of vaccination. This surely makes it one of the directions in which vaccine development is heading.
• Collaborative Global Initiatives: International collaborations have never been more important in addressing global health issues. Governments, pharmaceutical companies, and NGOs are engaging in vaccine research and dissemination by sharing or providing available resources. Such collaborations are helping improve vaccination coverage in neglected regions of the world, thus improving how viral threats are tackled worldwide.
• Emergence of Novel Vaccine Platforms: New vaccine modalities like viral vector vaccines and nanoparticle vaccines are becoming more common. These platforms offer benefits like improved safety percentages and greater immunogenicity. With these futuristic technologies in research, more effective vaccines will be engineered, and more viral diseases targeted.
• Enhanced Surveillance and Response Systems: The expansion of the viral vaccine market has also prompted the use of advanced surveillance equipment for tracking and monitoring vaccine efficacy against targeted viruses. Emerging data mining techniques and timely surveillance are making it more effective to deal with new viral threats. This preemptive measure allows for advancements in vaccination efforts and strengthens public health systems.
These developments are changing the dynamics of the viral vaccine market. By streamlining development processes, fostering international collaborations, and exploring new technologies, the sector is better positioned to combat present and future viral problems.
Strategic Growth Opportunities for Viral Vaccine Market
Vaccination against viruses presents numerous strategic possibilities for stakeholders due to public health dynamics and changing technologies. An overview of what stakeholders can do to increase their market share and take advantage of emerging opportunities highlights five key growth areas.
• Expansion of Vaccination Programs: Governments in different countries are taking measures to extend vaccination coverage to improve population health and prevent a wider range of viral diseases, including seasonal influenza and new viruses. This trend presents opportunities for vaccine manufacturers, who can design vaccines specific to certain populations. In such instances, partnerships with public health institutions would enrich the use of their products, especially if included in national immunization programs.
• Investment in Research and Development: To drive changes in the viral vaccine market, R&D investment is fundamental. These companies will focus on next-generation vaccines that fill medical gaps and address emerging viral diseases. A focus on R&D will enable companies to create better products, improve efficacy, and expand business alliances with research institutes.
• Adoption of Digital Health Technologies: The introduction of digital health technologies into vaccination programs opens up opportunities to improve vaccine delivery and monitoring. Apps and telemedicine can serve patients’ needs by providing education, appointments, and follow-ups. Companies that realize the potential of digital solutions for vaccines and apply them in strategies aimed at patients will enhance engagement and simplify the immunization process, thus increasing vaccination rates.
• Increasing Revenues in Emerging Markets: Emerging markets represent growth opportunities for the viral vaccine industry. With healthcare facilities improving and awareness regarding vaccination increasing, vaccine demand is expected to rise. Manufacturers can develop relationships with child health organizations in remote areas to distribute vaccines and reach untapped markets.
• Focusing on Prevention: A trend toward preventive health care is creating room for vaccine makers to market their products as an essential part of health care. Given the increase in health awareness among consumers, advocates of vaccination can promote disease prevention through vaccines, driving demand. Businesses can allocate resources toward campaigns and education for vaccination as a preventive measure to increase sales.
The innovative profit-making opportunities in the viral vaccine market highlight that the industry is not stagnant. Increasing vaccination programs, investing in R&D, and using digital health technologies are strategies that will benefit market players and positively influence global wellness.
Viral Vaccine Market Driver and Challenges
The viral vaccine market can be booming, growing, and creating many driving forces, as well as many market forces and challenges antagonizing growth. Understanding such market leaders and antagonists includes technology, laws, and other policies, as well as the market itself. As marketers, these drivers and challenges are critical in attempting to get the market and sub-markets in viral vaccine planning and development.
The factors responsible for driving the viral vaccine market include:
• Raising global health awareness: Revenue comes from growing public awareness regarding health or the importance of vaccination, which is the prime engine driving the viral vaccine market. There is a campaign to enlighten people about the merits of vaccines, and this has fostered interest in viral vaccines. As people become more health-savvy, there may be an expansion in the acceptance of vaccines and even in the utilization of vaccinated products.
• Technological innovations in vaccine development: The introduction of new technologies into the field of vaccine development, such as mRNA and viral-vector platforms, is changing the dynamics of the market. These developments help shorten the time frame required for development and increase the effectiveness of the vaccines, thus drawing the attention and investment of the pharmaceutical sector. Technological advancements will probably bring along new and better vaccines that will meet the ever-changing demands of the public health sector.
• Regulatory support for vaccine approvals: The existing regulatory and other policy frameworks and systems predominantly do not hinder the rapid provision of vaccines that have been developed. There are policies that help enhance the approval of new and advanced vaccines, especially during the pandemic. This trend creates a favorable environment for vaccine development and prompts sponsors to spend more resources on research and development.
• Emergence of new viral threats: The development of new viral threats, such as a novel coronavirus and other pathogens, and the need for vaccines to be developed for these, clearly demonstrates the necessity for vaccines to be created. Increased investments geared towards surveillance and preparedness activities are driving growth in vaccine research to safeguard public health systems from new viral threats in the future.
• Collaborative global initiatives: The efforts of governments, organizations, and private companies to enhance vaccine research and distribution in no way undermine the contributions of partnerships. Such partnerships promote the sharing of information, resources, and swift action in tackling the spread of any virus. Collaborative efforts are essential for enhancing vaccine equity for all people and reducing health inequities.
Challenges in the viral vaccine market are:
• Supply chain disruptions: As indicated by the COVID-19 pandemic, the viral vaccine market is exposed to supply chain disruptions. Problems in the procurement of raw materials, production, and many other such spheres can affect the availability of vaccines. Recent product shortages in the market reveal that companies need to come up with robust supply chain plans that can ensure product stocking without fail, even during peak seasons.
• Vaccine hesitancy: Population immunity, which is vital for the eradication of diseases, is hardly achieved due to vaccine hesitancy. Incorrect details regarding vaccines or guaranteed savings from vaccine promotional campaigns lead people to avoid vaccination programs. To increase vaccination rates and improve public health, the issue of vaccine hesitancy must be dealt with through education and community awareness.
The viral vaccine market is influenced by various factors, such as higher global health awareness and technological advancements. However, such growth will require addressing other issues like supply chain disruptions and vaccine hesitancy. Being cognizant of these strategic options is equally important for other players in this fast-changing environment.
List of Viral Vaccine Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies viral vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the viral vaccine companies profiled in this report include-
• CSL
• Pfizer
• Mitsubishi Tanabe Pharma
• Sanofi
• GlaxoSmithKline
Viral Vaccine by Segment
The study includes a forecast for the global viral vaccine by type, indication, distribution channel, and region.
Viral Vaccine Market by Type [Analysis by Value from 2018 to 2030]:
• Preventive Vaccine
• Therapeutic Viral
Viral Vaccine Market by Indication [Analysis by Value from 2018 to 2030]:
• Influenza
• Human Papilloma Virus
• Hepatitis
• Measles/Mumps/Rubella
• Others
Viral Vaccine Market by Distribution Channel [Analysis by Value from 2018 to 2030]:
• Hospital & Retail Pharmacies
• Government Suppliers
• Others
Viral Vaccine Market by Region [Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Viral Vaccine Market
The market for viral vaccines has notably improved in the recent past, especially after the global pandemic caused by COVID-19. The world is pouring in many resources into the production, distribution, and administration of vaccines for different viral diseases. This report shows a comprehensive picture of the latest trends in the development of viral vaccines in the US, Chinese, German, Indian, and Japanese markets, where the focus is still on marketing innovations and ensuring the good health of the population.
• United States: In the quest to develop and produce vaccines against viral diseases, the United States remains the leader in viral vaccine development. Here, most of the leading pharmaceutical companies and research institutions are located. The introduction and global distribution of COVID-19 mRNA vaccines accelerated the development of this technology, and research has started on vaccines against other viruses, including influenza and RSV. In addition, steps are being taken to improve the delivery and distribution of vaccines to other regions, covering more of the population.
• China: China emerged as a leader in the viral vaccine market due to the development of new sources of manufacture and efficient R&D processes. Several COVID-19 vaccines were developed in this country and used domestically as well as exported to other countries. Recent developments include multivalent vaccines that can provide protection against multiple prevalent strains of viruses, thus increasing the efficacy and coverage of vaccines against future challenges. Further, China is extending its vaccine distribution network to other remote parts of the world.
• Germany: Germany repeatedly helps out the world in the matter of viral vaccine development, especially in the field of advanced vaccine development. The country has remarkable biopharmaceutical companies investing in research on next-generation vaccines, such as those based on viral vectors. New efforts have focused on accelerating vaccine development and commercialization by government support. Additionally, Germany is enhancing the vaccine cold chain and last-mile distribution rather than developing new vaccines or adapting existing ones.
• India: India remains one of the important players in the world viral vaccine market, particularly in the areas of vaccine manufacturing and distribution in bulk. Recently, the PLI scheme was announced to enhance domestic manufacturing capabilities and promote development. Firms are also working on vaccines for new viral infections and enhancing their research arms. Engagements with other countries are improving India’s capacity to address global health problems.
• Japan: Japan is seeking other paths to advance its position in the viral vaccine market by making investments in biotechnology and improving healthcare system interventions. The state placed a number of necessary orders regarding vaccine creation through monetary support, as well as contracts with large pharmaceutical companies. Recent progress includes creating new types of vaccines against seasonal flu and the beginning of studies on vaccines based on peptides. Japan is taking steps to improve the regulatory system as well as the quality control system for the speedy availability of vaccines for new target organisms.
Features of the Global Viral Vaccine Market
Market Size Estimates: Viral vaccine market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Viral vaccine market size by type, indication, distribution channel, and region in terms of value ($B).
Regional Analysis: Viral vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, indications, distribution channels, and regions for the viral vaccine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the viral vaccine market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What is the viral vaccine market size?
Answer: The global viral vaccine market is expected to reach an estimated $76.3 billion by 2030.
Q2. What is the growth forecast for viral vaccine market?
Answer: The global viral vaccine market is expected to grow with a CAGR of 8.1% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the viral vaccine market?
Answer: The major drivers for this market are increasing prevalence of infectious diseases, increase in funding for the development of new vaccines, and rise in chronic infections among population.
Q4. What are the major segments for viral vaccine market?
Answer: The future of the viral vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier markets.
Q5. Who are the key viral vaccine market companies?
Answer: Some of the key viral vaccine companies are as follows:
• CSL
• Pfizer
• Mitsubishi Tanabe Pharma
• Sanofi
• GlaxoSmithKline
Q6. Which viral vaccine market segment will be the largest in future?
Answer: Lucintel forecasts that preventive will remain the larger segment over the forecast period.
Q7. In viral vaccine market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the viral vaccine market by type (preventive vaccine and therapeutic viral), indication (influenza, human papilloma virus, hepatitis, measles/mumps/rubella, and others), distribution channel (hospital & retail pharmacies, government suppliers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Viral Vaccine Market, Viral Vaccine Market Size, Viral Vaccine Market Growth, Viral Vaccine Market Analysis, Viral Vaccine Market Report, Viral Vaccine Market Share, Viral Vaccine Market Trends, Viral Vaccine Market Forecast, Viral Vaccine Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.